Phone: (707) 546-5553
Email Us
1140 Sonoma Avenue 1-A
Santa Rosa, CA 95405

Monthly Archives: October 2016

Dr. Michael Lazar of California HIFU was recently selected as top urology specialist by Sonoma Magazine’s Top Doctors survey

Dr. Michael Lazar, a Santa Rosa urologist and prostate cancer expert, is the only Northern California physician recognized as a leader in the use of high-intensity focused ultrasound (HIFU) for prostate cancer.

lazar close upSonoma Magazine’s Top Doctor survey was submitted to Sonoma County doctors who were then asked which medical specialist they would most often recommend to a loved one, and 327 professionals emerged as top docs in 50 categories of medicine. Among physician peers Dr. Lazar rose to the top in the field of urology, supporting what the many patients who rely on Dr. Lazar’s expertise already know.

Take for example the experience of Charles Lawrence a urology patient of Dr. Lazar. When Lawrence thought he was having urinary problems he sought out Dr. Lazar for a consultation. The exam proved to be even more important to his health when Dr. Lazar discovered an unrelated lump on Lawrence’s thyroid, recommending follow-up with a surgeon who later removed the nodule.

“Dr. Lazar discovered a nodule in my thyroid because he was thorough in his evaluation. It’s as straightforward as that, and I cannot be more appreciative of his comprehensive approach to treating patients,” Lawrence said.

About Dr. Lazar

Dr. Lazar graduated from the University of Arkansas in 1978 and completed postgraduate training in surgery and urology at LSU in 1983. He is four-time board certified by the American Board of Urology and Managing Physician Director of Santa Rosa Surgical Management Co., LLC, which manages Santa Rosa Memorial Hospital’s Ambulatory Surgery Center. He also serves as the Chairman of the Board of Directors of Redwood Health Services and as a member of the American Urological Association.

Dr. Lazar is part of Northern California Medical Associates and operates California HIFU in Santa Rosa. He is the medical director of HIFU Prostate Services, LLC, a leading provider of minimally-invasive prostate cancer treatments using High Intensity Focused Ultrasound (HIFU). Dr. Lazar is also a clinical partner with HPS with the HIFU San Francisco Surgery Center of Excellence, a state-of-the-art facility that is convenient to hotels and the airport.  

HIFU: Non-invasive Treatment for Prostate Cancer

HIFU is a FDA approved precise and targeted therapy for the treatment of prostate cancer, that reduces the risk of complications caused by surgery and radiation. HIFU uses ultrasound energy, or sound waves, to heat and destroy specifically targeted areas of tissue. During HIFU, the sound waves pass through healthy tissue without causing damage. At the focal point of the sound waves (like a magnifying glass focusing the rays of the sun to burn a leaf), the tissue temperature is raised to 90 degrees Celsius, destroying the targeted tissue.

Dr. Michael Lazar is the only Northern California physician and prostate cancer expert recognized as a leader in the use of high-intensity focused ultrasound (HIFU). He has been successfully treating patients with HIFU since 2007.

“HIFU has produced oncological results that are broadly comparable to standard therapies and HIFU is the only noninvasive prostate cancer therapy that does not use ionizing radiation11, which can be potentially harmful,” explains Dr. Lazar.

What HIFU Patients Have to Say

lockheed-comment-and-picHIFU patients are benefiting from Dr. Lazar’s expertise and comprehensive approach as well. One such patient, Chris Lockheed of Santa Rosa, CA, came to Dr. Lazar after a biopsy revealed that he had two tumors on his prostate. Lockheed, 68, had earlier started doing research into what kind of options for treatment were available to him. When a radiation specialist in Rohnert Park told him about Dr. Lazar and the HIFU procedure, he did more homework. He found that Dr. Lazar had done hundreds of these procedures in Puerto Vallarta, and the treatment was given FDA approval last October.

“Dr. Lazar explained everything, and he’s done over 300 of the procedures, that’s why I went to him. I felt very confident. I looked at all of the choices and said ‘this is for me’.” Last spring Lockheed drove down to the San Francisco Surgery Center for the three-hour outpatient procedure. Afterwards, feeling no side effects, Lockheed got some take-out food and drove home. Chris also mentioned he needed no pain medication. The only side effect he had was the catheter, which was “a little irritating.” After getting the catheter removed Lockheed reported that, “… everything was totally normal.” A week after the procedure he was back at work, drumming on the weekend, and working in the yard.

For more information about Dr. Lazar, HIFU treatment for prostate cancer visit the HIFU website or to make an appointment call: (707) 546-5553.

By | October 18th, 2016|News, Testimonials|0 Comments

California HIFU Patients Tell Their Stories

California HIFU Patients Tell Their Stories

– NEW VIDEO – Cancer patients who have opted for High Intensity Focused Ultrasound (HIFU), a noninvasive prostate cancer treatment offered by Dr. Michael Lazar of California HIFU, speak out about why they chose HIFU over other options, and what they have experienced as a result. Click on the video below to watch.

About California HIFU

High-intensity focused ultrasound or HIFU has many proven advantages over traditional treatment modalities for prostate disease. For more information about HIFU treatment or to make an appointment call: (707) 546-5553 or visit our website: www.californiahifu.com
By | October 10th, 2016|HIFU, News|0 Comments

Researchers say genomic fingerprinting important for treating prostate cancer

While the majority of prostate cancers are slow growing and not fatal, some are aggressive and lethal. Genomic fingerprinting can help predict a tumor’s aggressiveness and tailor treatment plans; however, in the majority of cases involving multiple prostate tumors, only the largest tumor is typically fingerprinted — resulting in more aggressive tumors potentially going undetected.

Writing in the journal European Urology, a research team led by Hannelore Heemers, Ph.D., of Cleveland Clinic’s Lerner Research Institute Department of Cancer Biology, and James Mohler, M.D., chair of the Department of Urology at Roswell Park Cancer Institute in Buffalo, has demonstrated that when genomic fingerprinting is performed on only a single tumor sample, a smaller but more aggressive tumor could potentially be missed.

The finding underscores the importance of new evidence that prostate tumors can be genetically different within an individual patient, which carries important implications for patients and oncologists.

For the study, “Intratumoral and Intertumoral Genomic Heterogeneity of Multifocal Localized Prostate Cancer Impacts Molecular Classifications and Genomic Prognosticators,” the team used next-generation sequencing techniques to genotype prostate tumors from four men who underwent radical prostatectomy at Roswell Park. They also examined public data from the Cancer Genome Atlas to confirm their findings.

“We examined the molecular composition of heterogeneous cancerous tumors in a patient’s prostate. We found a lot of genetic differences among these tumors, and concluded that information from a single cancer biopsy is not sufficient to guide treatment decisions,” said Dr. Heemers. “Precise treatment is more complicated and the findings demonstrate a weakness in current genetic fingerprinting in prostate cancer.”

“High risk prostate cancers differ genetically among patients, among the different tumors within an individual patient and even within different sections of a single tumor,” said Dr. Mohler. “Clinicians need to be careful about using the information from a gene-based test, because the analysis may not have been performed on the most aggressive portion of a man’s prostate cancer.”

In “Disrupting the Status Quo in Prostate Cancer Diagnosis,” an editorial published in the same journal, Alastair David Lamb, MB.ChB., Ph.D., of Cambridge University Hospitals, and co-authors write: “Several aspects of this study are impressive. [The authors] addressed an important clinical and molecular question: What effect does tumor heterogeneity have on decision making in prostate cancer, specifically, with respect to molecular taxonomies of the disease?”

The study authors note that the use of genomic analysis to personalize treatment plans is in its infancy and that many more large studies will be required to develop next-generation prognostic tools that can be relied on to guide treatment selection and planning for men with prostate cancer.


Story Source:

Materials provided by Cleveland Clinic. Note: Content may be edited for style and length.

Source: “One single biopsy not sufficient to guide treatment decisions in prostate cancer, say researchers.” ScienceDaily. ScienceDaily, 22 September 2016.

About California HIFU

High-intensity focused ultrasound or HIFU has many proven advantages over traditional treatment modalities for prostate disease. For more information about HIFU treatment or to make an appointment call: (707) 546-5553 or visit our website: www.californiahifu.com

By | October 4th, 2016|News, Prostate Cancer|0 Comments